ADU-S100

DRUG2 trials

Sponsors

Chinook Therapeutics, Inc. (formerly Aduro)

Conditions

Advanced/Metastatic Solid Tumors or LymphomasMetastatic Head and Neck CancerRecurrent Head and Neck Cancer

Phase 1

Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

TerminatedNCT02675439

Chinook Therapeutics, Inc. (formerly Aduro)Advanced/Metastatic Solid Tumors or Lymphomas

Start: 2016-04-28End: 2020-08-06Updated: 2021-12-30

Phase 2

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

TerminatedNCT03937141

Chinook Therapeutics, Inc. (formerly Aduro)Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

Start: 2019-08-26End: 2021-06-10Updated: 2022-01-03

Related Papers

Abstract 1877: Measurement of cytosolic DNA sensing cGAS-STING pathway functional activity using <i>in vitro</i> phenotypic assay models

Cancer Research2022-06-15

CASTING: A Potent Supramolecular Strategy to Cytosolically Deliver STING Agonist for Cancer Immunotherapy and SARS-CoV-2 Vaccination

CCS Chemistry2022-05-1752 citations

The Age of Cyclic Dinucleotide Vaccine Adjuvants.

2020-08-1374 citations

Abstract A050: Intratumoral delivery of a novel STING agonist synergizes with checkpoint blockade to regress multifocal pancreatic cancer

Cancer Immunology Research2019-02-012 citations

Activity of a Sting and a TLR9 Agonist As an “in Situ Therapeutic Vaccination” Against Lymphomas

Blood2016-12-021 citations